A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys

Megumi Morimoto | Masuo Yamaoka | Takahito Hara

Abstract
SARM-2f a selective androgen receptor (AR) modulator, increases skeletal muscle mass and locomotor activity in rats. This study aimed to clarify its pharmacological effects in monkeys. In reporter assays, the EC$_{50}$ values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively. A single oral administration (10 mg/kg SARM-2f) produced a maximal plasma concentration of 3011 ng/mL, with an area under the 24-hours concentration-time curve of 8152 ng·h/mL in monkeys. Body weight (BW), lean body mass (LBM), and plasma levels of total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, lipoprotein (a), alanine aminotransferase, and asparagine aminotransferase were measured after 4 weeks of treatment with SARM-2f (1, 3, and 10 mg/kg/day, QD, p.o.) or testosterone enanthate (TE; 2 mg/kg/2 weeks, s.c.) in monkeys. BW and LBM were significantly increased by 12% each by SARM-2f at 10 mg/kg, and by 5% and 8%, respectively, by TE, but these effects were not statistically significant. Plasma levels of all lipids were either decreased or showed a tendency to be decreased by SARM-2f. TE decreased the triglyceride level and increased the low-density lipoprotein cholesterol level. Liver marker levels were not changed by either SARM-2f or TE. Our data demonstrated that SARM-2f exerted anabolic effects and produced a lipid profile that differed from that produced by testosterone in monkeys, suggesting that SARM-2f might be useful for diseases such as sarcopenia.

KEYWORDS
body weight, cholesterol, lean body mass, monkey, sarcopenia, selective androgen receptor modulator, testosterone

1 | INTRODUCTION
Age-related sarcopenia or cachexia is associated with a decrease in muscle mass and strength; this reduces the quality of life and increases nursing care requirements and mortality. Sarcopenia and cachexia represent unmet needs, and the sarcopenia medical care guidelines were established recently. Medication provides one treatment option, and the ghrelin agonist anamorelin was approved for this...
condition in the USA in 2017. Anamorelin increased body weight and muscle mass and improved anorexia in cancer cachexia. However, anamorelin did not improve grip strength. In contrast, testosterone can improve muscle strength. However, there is a concern that long-term testosterone use may cause adverse cardiovascular events because of its impact on the blood lipid profile. Thus, the development of alternative therapeutic agents is required.

Selective androgen receptor modulator (SARM) compounds, such as ostarine, significantly increased body weight, muscle mass, and muscle strength in preclinical rodent studies, and increased muscle mass in clinical trials. Our non-steroidal small molecule, SARM compound, SARM-2f (4′-[(2S,3S)-2-Ethyl-3-hydroxy-5-oxopyrrolidin-1-yl]-2′-trifluoromethyl benzonitrile), also increases muscle weight and stimulates motor activity, food intake, and sexual behavior in rodent models. Currently, there are only a few reports showing the pharmacological effect of SARM compounds in monkeys: effects on blood high-density lipoprotein cholesterol (HDL-c) and overall gene expression profiles in the muscle. In this study, we investigated the pharmacological effects of SARM-2f in cynomolgus monkeys in vitro and in vivo. The androgen receptor (AR) activation of monkey AR was examined by reporter assays, the anabolic effects were assessed using body weight (BW) and lean body mass (LBM), and the potential cardiovascular or liver side effects were assessed by blood biochemistry tests. This study shows the anabolic effect of a SARM compound, SARM-2f, together with its favorable effect on the blood lipid profile in monkeys.

2 | MATERIALS AND METHODS

2.1 | Reagents

SARM-2f (Lot No. B23444-084-10) was synthesized by Takeda Pharmaceutical Company Limited. Ostarine was purchased from Cayman Chemical Company. Testosterone and dihydrotestosterone (DHT) were purchased from TCI Chemicals (Tokyo, Japan). Testosterone enanthate (TE; ENARMON DEPOT Intramuscular injection 125 mg) was purchased from Asuka Pharmaceutical. Methylcellulose and sesame oil were purchased from Shin-Etsu Chemical and Maruishi Pharmaceutical, respectively.

2.2 | AR reporter assays

COS7 cells were transfected with 0.49 µg of either human AR (pcDNA3.1(−)/hAR), rat AR (pcDNA3.1/rAR), or cynomolgus monkey AR (pcDNA3.3/mfAR), together with 19.5 µg pGL4.36/MMTV-luc, using Superfect Transfection Reagent (QIAGEN) according to the manufacturer’s instructions. Two hours post-transfection, the cells were plated in 96-well plates at a density of 2 × 10^4 cells/well, and cultured at 37°C for 3 hours. SARM-2f, ostarine, or testosterone were then added to the wells and incubated at 37°C for 24 hours. Luciferase activity was measured using the Steady-Glo Luciferase assay system (Promega) and an Envision Multimode Plate Reader (PerkinElmer). Compound activity was calculated with 1 µmol/L DHT activity set at 100%.

2.3 | Animals

All animal studies were performed at SNBL Japan; the animals were maintained in accordance with the rules of the Institutional Animal Care and Use Committee of Takeda Pharmaceutical Company Limited. The animals were purpose-bred Chinese cynomolgus monkeys. In the single-dose pharmacokinetic test, two males and two females aged 5-7 years were used. For the multi-dose efficacy test, 20 males aged 3-4 years were purchased and allowed to habituate for two weeks. Fifteen animals were selected based on their weight and appropriateness for administration. The experiments were conducted in an individual breeding environment with a 12 hours light/dark cycle (light period 07:00-19:00 hours), a temperature of 23°C-29°C, and 35-75% humidity. The monkeys received 9 × 12 g pellets of diet (HF Primate 5K91 12G 5K9J) once daily at 14:30-16:00 hours; this was retrieved the next morning at 08:30-10:00 hours (before dosing). Fresh apple or sweet potato was provided more than twice a week, except on the day of measuring BW and collecting blood. Water was available ad libitum. Toys were provided continuously.

2.4 | Pharmacokinetic study

Monkeys were orally treated with SARM-2f (10 mg/kg) as a single dose or daily administration for 14 consecutive days; blood was collected from the femoral vein at 0.5, 1, 2, 4, 8, and 24 hours after the single dose and 14 doses (n = 2 each sex). The blood samples were centrifuged (4°C, 12 000 g, 1 minutes) to obtain plasma. Plasma concentrations of SARM-2f were measured by liquid chromatography/tandem mass spectrometry.

2.5 | Effects on body weight, lean body mass, and blood biochemistry

The monkeys were divided into five groups by weight randomization (MITOX system ver2.0, Mitsui E & S Systems Research Inc) on the last day of the habituation period. SARM-2f was orally administered at daily doses of 1, 3, or 10 mg/kg for 4 weeks between 9:00 and 11:00 hours, using 0.5% w/v methylcellulose as the vehicle. TE was injected intramuscularly on Day 0 and Day 13; the dosing start was set at Day 0 at a dose of 2 mg/kg using sesame oil as the vehicle. The route of administration and dose of TE was selected according to the route and dose mentioned in the clinical indications. BW was measured every week before dosing (between 8:30 and 9:00 hours), and LBM was measured every 2 weeks after dosing and before feeding (between 11:30 and 14:30 hours) using an X-ray bone density measuring device (Discovery, HOLOGIC USA). Blood collection for lipid profiles was conducted on the day after the completion of the four-week multiple administration.
of SARM-2f or TE. Plasma levels of total cholesterol (T-chol), HDL-c, low-density lipoprotein cholesterol (LDL-c), triglyceride (TG), alanine aminotransferase (ALT), and asparagine aminotransferase (AST) were measured by an automatic JCA-BM8 analysis system (JEOL Ltd.). Plasma lipoprotein (a) (Lp (a)) levels were measured using a multiplate absorbance measuring system (Multiscan Ascent, Thermo Fisher Scientific KK). Plasma testosterone levels were measured using a testosterone measurement kit (TESTO-CTK, DiaSorin Inc Saluggia Italy).

2.6 | Statistical analysis

In the reporter assays, EC$_{50}$ was calculated using Graph Pad Prism version 6. The effects of SARM-2f or TE on BW and LBM were analyzed by t test, with Bonferroni correction for repeated measurements. The effects of SARM-2f on lipid levels and ALT/AST levels were analyzed by Dunnett’s test after ANOVA using the SAS software system, and those of testosterone were analyzed by Student’s t test. P < .05 was considered statistically significant.

3 | RESULTS

3.1 | Activation of monkey, human, and rat AR by SARM

For monkey AR, the dose-response curves for SARM-2f, ostarine, and testosterone were similar over the concentration range of $10^{-12}$ to $10^{-8}$ mol/L, with respective EC$_{50}$ values of 3 (confidence interval (CI): 1.2-7.2), 2.2 (CI: 1.2-4.1), and 3.2 (CI: 1.4-7.2) nM (Figure 1A). The maximal AR activation was 125% and 126% for SARM-2f and ostarine at 1 μmol/L, respectively, where the activation by DHT at 1 μmol/L was set to 100% (Figure 1A). The activation by 1 μmol/L testosterone was very similar, at 99% of 1 μmol/L DHT activation. For human AR, the slopes of the SARM-2f and ostarine dose-response curves were steeper than that of testosterone, with EC$_{50}$ values of 3.6 (CI: 2.1-6.2), 2.7 (CI: 1.3-5.5), and 11 (CI: 7.5-17) nmol/L, respectively (Figure 1B). The maximal activation levels were 140%, 141%, and 107% for SARM-2f, ostarine, and testosterone, respectively, at 1 μmol/L (Figure 1B). For rat AR, the dose-response curves of SARM-2f and ostarine shifted to lower concentrations, compared to that of testosterone (Figure 1C), and the EC$_{50}$ values were 2.5 (CI: 1.4-4.3), 2.5 (CI: 1.3-4.5), and 12 (Cl: 7.1-20) nM, respectively (Figure 1C). The maximal activations were 118, 112, and 113% for SARM-2f, ostarine, and testosterone, respectively, at 1 μmol/L (Figure 1C). A preliminary reporter assay was conducted in a similar manner. Similar results were obtained from a total of two experiments.

3.2 | Pharmacokinetics of SARM-2f in monkeys

Following a single oral dose of 10 mg/kg SARM-2f, the maximal plasma level ($C_{max}$) was 3011 ng/mL; this was observed at 1.0 hours ($T_{max}$), and the area under the plasma concentration-time curve (AUC$_{0-24h}$) was 8152 ng·h/mL (n = 2 each sex, Table 1). The $T_{max}$, $C_{max}$, and AUC$_{0-24h}$ observed on the day after the 14 days of daily oral treatments did not differ from those observed after the single oral administration (Table 1). The blood concentration curves are shown in Figure S1.

3.3 | Increase of BW and LBM during four-week administration of SARM-2f to monkeys

In the vehicle control animals, the BW gains from the pre-dosing level (Day −1 when dosing start was set at Day 0) to Day 13 and Day 27 were 2.4% and 1.8%, respectively (Figure 2A, Table S1). In contrast, animals receiving daily doses of SARM-2f at 1, 3, and 10 mg/kg increased BW by 6.2%, 6.0%, and 8.7%, respectively, on Day
on Day 27 in animals treated with 10 mg/kg SARM-2f was statistically significant (Figure 2A).

Blood chemistry

Blood levels of T-chol, LDL-c, and TG were lower following daily treatment with SARM-2f at 1, 3, and 10 mg/kg (Figure 3A-C), while the HDL-c level was only reduced in animals treated with 3 or 10 mg/kg (Figure 3D). SARM-2f did not cause any significant change in the HDL-c/LDL-c ratio (Figure 4E). The Lp (a) protein level showed a tendency to decrease by SARM-2f (Figure 3F), but this effect was not statistically significant. TE did not affect the blood levels of T-chol, HDL-c, or Lp (a) (Figure 3A,D,F), but did reduce the TG level and increase the LDL-c level significantly (Figure 3C,B). The blood levels of AST and ALT were not changed by either SARM-2f or TE (Figure 4A,B).
3.5 | Plasma testosterone level

Blood testosterone levels were measured before the dosing started (Day −11), and 2 weeks after the second dose (Day 27) in the vehicle and TE groups. In the TE group, all monkeys showed an increase on Day 27, as compared with pre-dosing levels (Table 2); the average concentration changed from 1.0 ng/mL on Day −11 to 4.2 ng/mL on Day 27 (Table 2). In the vehicle group, one of the three animals showed an increase over time (Table 2); this individual also showed gains in LBM and BW (Figure 2). The testosterone levels of the remaining two animals did not increase during vehicle treatment (Table 2).

4 | DISCUSSION

Sarcopenia is defined as an age-associated loss in skeletal muscle function and muscle mass. The recent treatment guidelines issued by the International Conference on Sarcopenia and Frailty Research strongly recommend the prescription of resistance-based physical activity, and
**TABLE 2** Individual plasma testosterone levels in male cynomolgus monkeys before and after the indicated 4-week treatments

| Treatment                | Animal No. | Testosterone concentration (ng/mL) |
|--------------------------|------------|-----------------------------------|
|                          |            | day-11 | day27 |
| Vehicle control          | 1          | 1.06   | 3.75  |
|                          | 2          | 0.97   | 1.24  |
|                          | 3          | 0.34*  | 0.36  |
| Mean                     |            | 0.79   | 1.78  |
| SD                       |            | 0.39   | 1.76  |
| Testosterone enanthate   | 1          | 1.03   | 7.00  |
|                          | 2          | 0.34*  | 1.78  |
|                          | 3          | 1.71   | 3.92  |
| Mean                     |            | 1.03   | 4.23  |
| SD                       |            | 0.69   | 2.62  |

*Reanalysis values. When samples were measured after 2-fold dilution and were below the lower limit of quantification (0.3 ng/mL), they were reanalyzed without dilution, and these values were presented.

Although the TE administration group showed a tendency for an increase in BW and LBM, it was not statistically significant. We were able to maintain the blood testosterone concentration necessary for clinical treatment of hypogonadism as described above. In additions, the EC50 values of SARM-2f and testosterone were almost equal for monkey AR, and the AUC0-24h level was estimated to be higher for testosterone than SARM-2f. Therefore, it is unlikely that the efficacy of TE was weak because of lower exposure of testosterone compared to SARM-2f. Furthermore, it is reported that TE intramuscular administration at 20 mg/kg significantly increasing the BW of monkeys within 4 weeks, where the blood testosterone nadir levels is approximately 1500 ng/dL. This is much higher than the blood testosterone nadir levels in this study. Collectively, this study did not record a significant increase possibly because of the small sample size.

It should also be noted that different doses were used for TE and SARM-2f in this study; ie 2 mg/kg im every 2 weeks for TE vs 1-10 mg/kg p.o. daily for SARM-2f. These administration routes for these drugs were chosen as per the best suitability of administration. TE was administered intramuscularly and we selected the dose of 2 mg/kg once every 2 weeks, mimicking the clinical regimen used in male hypogonadism (maximum 250 mg once every 2-4 weeks; this dose is indicated on the package insert of TE). In contrast, SARM-2f is a non-steroidal small molecule that was optimized for oral administration. Since drug metabolism and hence the pharmacodynamics differ between TE and SARM-2f, direct comparison of efficacy needs to be performed cautiously. The timing of efficacy measurements may affect the intensity and persistency of the drug effects.

We previously reported that SARM-2f increased skeletal muscle weight with a much lesser effect on prostate weight. The mechanisms for tissue selectivity of SARM includes two factors: recruitment of specific cofactors to AR and a tissue-specific cofactor expression profile. We reported that SARM-2f induced less recruitment of the protein inhibitors of the activated STATs family to the AR than did testosterone. The present study did not address
the tissue specificity of SARM-2f. Further research will be necessary to investigate its tissue specificity in monkeys.

The pharmacokinetic parameters were similar between rats and monkeys. The AUC_{0-24h} values after a single oral administration of SARM-2f at 1 mg/kg are 809.4 ng·h/mL and 557.8 ng·h/mL, respectively, and MRT (Mean Residence Time) was 3.06 and 5.21 hours, respectively, for rats and monkeys. The Vdss value after intravenous administration at 0.1 mg/kg was 2167 mL/kg and 1409 mL/kg for rats and monkeys, respectively. In this study, the effective dose to increase BW by approximately 10% in monkeys was 10 mg/kg, and the AUC_{0-24h} at 10 mg/kg was 8152 ng·h/mL. A dose of 0.3 mg/kg is sufficient to increase BW in rats. These findings indicate that monkeys required an approximately 30-fold higher drug exposure to gain BW, compared with rats.

In addition, 2 weeks or less of daily treatment with SARM-2f is enough to increase BW in rodents. In contrast, BW was not significantly increased after 2 weeks of daily treatment with SARM-2f at 10 mg/kg in this monkey study but was significantly increased at 4 weeks, suggesting that skeletal muscle increase in primates might require more time, as compared with rodents.

Monkeys were selected for the present study because we should examine the effect of SARM-2f on blood lipid profile. Rodent models are not suitable for pre-clinical studies of lipid profiles because they differ from humans by having very low LDL-c levels. Testosterone was reported to increase the blood LDL-c level and reduce the blood HDL-c level in patients with hypogonadism and in sexually mature monkeys. In the present study, TE treatment increased the LDL-c level but did not decrease the HDL-c level in monkeys. This may be because the animals used in this study were not sexually mature. SARM-2f decreased almost all of the lipid parameters measured in this study, including HDL-c, LDL-c, TG, and T-chol. In the recent years, an increase in the LDL-c/HDL-c ratio, and increased LDL-c levels, have been considered to represent risk factors for arteriosclerosis and myocardial infarction. Blood LDL-c and HDL-c levels were both decreased in monkeys treated with SARM-2f, while the LDL-c/HDL-c ratio remained unchanged or decreased.

It is currently unclear whether the level of Lp (a), a potent risk factor for heart disease, is suppressed by statins, a widely used class of hydroxymethylglutaryl-CoA reductase inhibitors. SARM-2f showed a tendency to reduce blood Lp (a) levels in monkeys. Further studies are required to confirm this effect.

Blood AST and ALT levels, which provide an index of liver function, were not affected by SARM-2f at 10 mg/kg in this study. Therefore, the changes in the blood lipid profile associated with SARM-2f administration were not caused by liver function deterioration.

It should also be noted that in 126 biochemical activity assays (enzyme assays or radioligand binding assays) provided by MDS Pharma Service-Taiwan Ltd., the only molecule that SARM-2f affected at 10 μmol/L was AR (Table S5). Based on these findings, we believe that SARM-2f has no severe off-target effects.

Taken together, these findings indicated that SARM-2f had fewer negative impacts on the lipid profile, as compared with testosterone. However, further studies are required to investigate the long-term effects of SARM-2f on lipid profiles in monkeys.

Several major international medical societies provide the guidelines for testosterone therapy for testosterone deficiency or hypogonadism. The consensus amongst the guidelines is that testosterone deficiency is defined based on both abnormal laboratory measurements and clinical signs. The laboratory thresholds vary amongst the organizations but are similar worldwide. The American Urological Association defines a low total testosterone as <300 ng/dL. Clinical signs include anemia, bone mineral density loss, male infertility, loss of muscle, increase in adiposity, and erectile dysfunction. The European Association of Urology, the International Society for Sexual Medicine, and the International Society for the Study of the Aging Male set a threshold of 350 ng/dL, and the British Society for Sexual Medicine set <345 ng/dL. The American Association of Clinical Endocrinologists declined to set a threshold but suggested that symptomatic men with testosterone levels <200 ng/dL may be potential candidates for testosterone therapy. In this study, it was necessary to use juvenile or elderly monkeys to mimic clinical settings where hypogonadism or sarcopenia patients have low blood testosterone levels. The reasons for choosing juvenile monkeys are as follows: (a) juvenile monkeys used in this study showed blood testosterone levels below the threshold defined as hypogonadism; (b) elderly monkeys have large individual differences in BW; (3) blood testosterone levels differ greatly among individuals from the age of 4 years under breeding conditions; and (4) longer-term drug administration, both in the case of SARM-2f and TE, was required in pharmacological studies to show significant increases in BW and LBM in older rats compared to juvenile rats (in-house data). These findings suggest that the treatment period required for pharmacological studies in elderly monkeys would be very long. Because of these reasons, we used juvenile monkeys.

Despite selecting the animals so carefully, one animal in the vehicle control group may have entered the sexual maturation phase because it showed increasing blood testosterone levels during the experimental period. Blood androgen levels increase during the sexual maturation period. Normal body growth of 14 male indoor-bred cynomolgus monkeys has been reported. The variation in BW increases with age, and 4-year-old male cynomolgus monkeys gain approximately 0.7 kg in half a year. This finding is consistent with our data in this study, where the vehicle treatment monkeys showed an increase of 0.1 kg in 4 weeks. Because of the animal in the vehicle group, it was slightly difficult to demonstrate the anabolic effects of SARM-2f.

One of the limitations of this study is that the responses to SARM may differ between immature animals with low testosterone levels and older animals with low testosterone levels. Further study will be necessary to investigate the effects of SARM-2f on older monkeys with low blood testosterone levels.

In elderly people or patients with metabolic wasting diseases, the ability to absorb protein and vitamins deteriorates, leading to muscle loss. Comprehensive therapeutic strategies combining exercise, nutritional control, and SARM treatment may therefore provide an effective approach to strengthening muscle power in patients with
sarcopenia or cachexia. In conclusion, SARM-2f demonstrated anabolic effects and hypolipidemic activity in monkeys. These findings warrant further study to explore whether SARM-2f could be used in humans.

CONFLICTS OF INTEREST STATEMENT

The authors have no conflict of interest to the content of this article.

ACKNOWLEDGEMENTS

We thank Takashi Santou and Jun-ichi Sakamoto in Axcellead Drug Discovery Partners Inc, for conducting reporter assays.

AUTHOR CONTRIBUTIONS

Morimoto, Yamaoka, and Hara participated in research design and conducted experiments. Morimoto performed data analysis. Morimoto and Hara contributed to the writing of the manuscript.

ORCID

Takahito Hara https://orcid.org/0000-0002-9941-9041

REFERENCES

1. Shafiee G, Keshkhar A, Soltani A, Ahadi Z, Larjani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16:21.
2. Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer cachexia: Beyond weight loss. J Oncol Pract. 2016;12:1171-1174.
3. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019;393:2636-2646.
4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010;3:412-423.
5. Dent E, Morley JE, Cruz-Jentoft AJ, et al. International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging. 2018;22:114-161.
6. Currow DC, Maddocks M, Cella D, Muscaritoli M. Efficacy of anaborelin, a novel non-peptide ghrilin analogue, in patients with advanced non-small cell lung cancer (NSCLC) and cachexia—review and expert opinion. Int J Mol Sci. 2018;19:3471. https://doi.org/10.3390/ijms19113471.
7. Storer TW, Basaria S, Traustadottir T, et al. Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men. J Clin Endocrinol Metab. 2017;102:583-593.
8. Loo SY, Azoulay L, Nie R, Dell’Aniello S, Yu OHY, Renoux C. Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study. Am J Med. 2019;132(9):1069-1077.e4
9. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
10. Tsimakis S, Goedts PLSM, Nora C, Yeang C, Witzum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2019;euh310.
11. Vajda EG, Lopez FJ, Rix P, et al. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrrole[3,2-f]quinoline-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. JPET. 2009;328:663-670.
12. Chisamore MJ, Gentile MA, Dillon GM, et al. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice. J Steroid Biochem Mol Biol. 2016;163:88-97.
13. Dubois V, Simitisdeilis I, Laurent MR, et al. Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the satellite cell lineage. Endocrinology. 2015;156:4522-4533.
14. Srinath R, Dobs A. Enobosarm (GTx-024, S-22): a potential treatment for cachexia. Future Oncol. 2014;10:187-194.
15. Aikawa K, Asano M, Ono K, et al. Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl) benzonitrile derivative 2f as a clinical candidate. Bioorg Med Chem. 2017;25:3330-3349.
16. Morimoto M, Amano Y, Oka M, et al. Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f. PLoS ONE. 2017;12:e0189480.
17. Morimoto M, Aikawa K, Hara T, Yamaoka M. Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models. OncoLett. 2017;14:8066-8071.
18. Saeed A, Vaught GM, Gavardinas KG, et al. 2-Chloro-4-[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3- methyl-benzonitrile: A transdermal selective androgen receptor modulator (SARM) for muscle atrophy. J Med Chem. 2015;59:750-755.
19. Papanicolau DA, Ather SN, Zhu H, et al. Phase IIa randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging. 2013;17(6):533-543.
20. Dalton JT, Barnett KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal womenresults of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153-161.
21. Coss CC, Jones A, Hancock ML, Steiner MS, Dalton JT. Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian Journal of Andrology. 2014;16(2):256-261.
22. Dobs AS, Bocci RC, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial. Lancet Oncol. 2013;14(4):335-345.
23. Riedmaier I, Tichopad A, Reiter M, Pfaffl MW, Meyer HHD. Influence of testosterone and novel SARM on gene expression in whole blood of Macaca fascicularis. J Steroid Biochem Mol Biol. 2009;114:167-173.
24. Ullah MI, Riche DM, d Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014;8:101-112.
25. Weinbauer GF, Parths CJ, Zittmann M, Schlitt S, Niescheg A. Pharmacokinetics and degree of aromatization rather than total dose of different preparations determine the effects of testosterone: a non-human primate study in Macaca fascicularis. J Endocrinol. 2003;24:765774.
26. Narayan R, Coss CC, Dalton JT. Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465:134-142.
27. Hikichi Y, Yamaoka M, Kusaka M, Hara T. Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile. Eur J Pharmacol. 2015;765:322-331.
28. Poleed R, Juricikova-Novotna L. Experimental models of hyperlipoproteinemia and atherosclerosis. Physiol Res. 2017;66:S59-575.
29. Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab. 2003;284:E1112-E1118.
30. Fernandez-Balsells MM, Murad MH, Lane M, et al. Adverse effect of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560-2575.
31. Weyrich AS, Rejeski WJ, Brubaker PH, Parks JS. The effects of testosterone on lipids and eicosanoids in cynomolgus monkeys. Med Sci Sports Exerc. 1991;24:333-338.
32. Kunutsor SK, Zaccardi F, Karppi J, Kurl S, Laukkanen JA. Is high serum LDL/HDL cholesterol ratio an emerging risk factor for sudden cardiac death? Findings from the KIHD study. J Atheroscler Thromb. 2017;24:600-608.

33. Boffa MB, Stranges S, Klar M, Moriarty PM, Watts GF, Koschinsky ML. Lipoprotein(a) and secondary prevention of atherothrombotic event: a critical appraisal. J Clin Lipidol. 2018;12:1358-1366.

34. Xu MX, Liu C, He YM, Yang X, Zhao X. Long-term statin therapy could be efficacious in reducing the lipoprotein(a) levels in patient with coronary artery disease modified by some traditional risk factors. J Thorac Dis. 2017;9:1322-1332.

35. Happner S, Orchard T, Stein E, Schmidt D, Labelle P. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol. 1995;18:261-267.

36. Pirillo A, Catapano AL. Statins increase Lp(a) plasma level: is this clinically relevant? Eur Heart J. 2019;ehz505.

37. Salter CA, Mulhall JP. Guideline of guidelines: testosterone therapy for testosterone deficiency. BJU Int. 2019;124(5):722-729.

38. Yoshida T, Suzuki K, Cho F, Honjo S. Age-related changes of hematological and serum biochemical value in cynomolgus monkeys (Macaca fascicularis) bred and reared using the indoor individual-caged system. Exp Anim. 1986;35:329-338.

39. Yoshida T. Physical growth and aging of the laboratory-bred cynomolgus monkey (Macaca fascicularis). Primate Res. 2009;24:345-355.

40. Mirsky ML, Portugal S, Pisharath H, Osowski JL, Kearney L. Utility of ochidometric parameters for assessing sexual maturation in male cynomolgus macaques (Macaca fascicularis). Comp Med. 2016;66:480-488.

41. Boirie Y, Guillet C. Fast digestive proteins and sarcopenia of aging. Curr Opin Clin Nutr Metab Care. 2018;21:37-41.

42. Landi F, Calvani R, Tosato M, et al. Protein intake and muscle health in old age: from biological plausibility to clinical evidence. Nutrients. 2016;8:295.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Morimoto M, Yamaoka M, Hara T. A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. Pharmacol Res Perspect. 2020;00:e00563. https://doi.org/10.1002/prp2.563